More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

AX-158 has achieved clinical validation through its phase 2a trial for the treatment of patients with mild to moderate plaque psoriasis, Artax Biopharma announced in a press release.

Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.

Sotyktu (deucravacitinib) is a brand-name oral tablet that’s prescribed for plaque psoriasis in certain adults ... who took Sotyktu in clinical trials: Mild side effects can occur with Sotyktu ...

The latest FDA approval was based on the results of the ADVANCE trial, which showed that five times as many adults with mild to moderate plaque psoriasis receiving oral Otezla 30 mg twice daily ...

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

Mild side effects that have been reported in people using Tazorac for plaque psoriasis include: In most cases, these side effects should be temporary, and some may be easily managed. But if you ...

Now, six months into the NSW Pharmacy Dermatology Trial, pharmacists are now also appropriately trained to manage impetigo ...

about 80% to 90% of people with psoriasis have plaque psoriasis. Most psoriasis patients have mild or moderate forms of the disease. The former means less than 3% of the body surface area is ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis ... the disease severity and even mild disease may have negative effects ...